| Bioactivity | Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models[1]. | ||||||||||||
| In Vivo | Nizatidine (oral gavage; 27 mg/kg; once daily; at 12 weeks of age and were sacrificed at 30 weeks after development of HCC in the setting of nonalcoholic steatohepatitis (NASH)) results in a 35% reduction of tumor nodules relative to controls. Nizatidine results in a 60% reduction in tumor nodules, reduces collagen proportional area and expression of profibrotic markers in DEN-injured rats[2].Nizatidine (oral gavage; 27 mg/kg; once daily; 4 weeks) decreases the incidence of gastric ulceration, and significantly decreases the mean ulcer score and ulcer index in male albino rats[3]. Animal Model: | ||||||||||||
| Name | Nizatidine | ||||||||||||
| CAS | 76963-41-2 | ||||||||||||
| Formula | C12H21N5O2S2 | ||||||||||||
| Molar Mass | 331.46 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. T M Lin, et al. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther. 1986 Nov;239(2):406-10. [2]. Shen Li, et al. Abstract 4004: The H2 receptor antagonist nizatidine inhibits carcinogenesis in two rodent models of hepatocellular carcinoma. Tumor Biology. Cancer research. [3]. Ahmed S. Alazzouni, et al. Comparative histological and histochemical studies between ranitidine and nizatidine in treatment of peptic ulcer with evaluation of their adverse effects on male sex hormones. The Journal of Basic and Applied Zoology volume |